Searchable abstracts of presentations at key conferences in endocrinology

ea0038p302 | Pituitary | SFEBES2015

Menin regulates the expression of miR-15a, which is downregulated and inversely correlates with cyclin D1 expression in mouse Men1-associated pituitary tumours

Lines Kate E , Newey Paul J , Yates Chris J , Walls Gerard V , Thakker Rajesh V

Multiple Endocrine Neoplasia type 1 (MEN1) is an autosomal dominant disorder characterised by the combined occurrence of parathyroid, pituitary and pancreatic islet tumours, and is due to mutations of the MEN1 gene, which encodes the tumour suppressor protein menin. MicroRNAs (miRNA) are non-coding single stranded RNAs that post-transcriptionally regulate gene expression. Alterations in miRNA expression, including downregulation of two miRNAs, miR-15a and miR-16-1, have been r...

ea0044p78 | Clinical biochemistry | SFEBES2016

Management of multiple endocrine neoplasia type 1 (MEN1) and sporadic pancreatic neuroendocrine tumours (PNETS) in relation to the clinical guidelines: a single centre audit

Ntali Georgia , Newey Paul J , Stokes Victoria , Talbot Denis , Soonawalla Zahir , Sadler Greg , Karavitaki Niki , Grossman Ashley B , Thakker Rajesh V

Introduction and aim: Pancreatic neuroendocrine tumours (PNETs) may occur sporadically (sPNETs) or as part of the multiple endocrine neoplasia type 1(MEN1) syndrome, which is characterised by occurrence of PNETs, parathyroid and anterior pituitary tumours. Our aim was to review the management of these patients in relation to the clinical practice MEN1 guidelines, and the ENETS and UKINETS guidelines for PNETs.Patients and methods: Patients attending with...

ea0034p174 | Neoplasia, cancer and late effects | SFEBES2014

Bromodomain inhibitors reduce proliferation and increase apoptosis of human neuroendocrine tumour cells

Lines Kate E , Stevenson Mark , Gaynor Katherine U , Newey Paul J , Piret Sian E , Lingard Hannah , Filippakopoulos Panagis , Muller Susanne , Grozinsky-Glasberg Simona , Grossman Ashley , Knapp Stefan , Schofield Chris , Bountra Chas , Thakker Rajesh V

Pancreatic neuroendocrine tumours (NETs) are reported to show frequent mutations in chromatin remodelling genes, while pituitary NETS have alterations in histone modification. Histone modifications, and specifically acetylated residues on histone tails are recognised by members of the bromo and extra terminal (BET) protein family, via their bromodomains, causing alterations in the transcription of growth stimulating genes. BET bromodomain inhibitors have been demonstrated to s...

ea0031p149 | Neoplasia, cancer and late effects | SFEBES2013

Epigenetic modifiers reduce proliferation of human neuroendocrine tumour cell lines

Lines Kate E , Gaynor Katherine U , Stevenson Mark , Newey Paul J , Piret Sian E , Filippakopoulos Panagis , Muller Susanne , Grozinsky-Glasberg Simona , Grossman Ashley B , Knapp Stefan , Schofield Christopher , Bountra Chas , Thakker Rajesh V

Neuroendocrine tumours (NETs), occurring at multiple sites including the pancreas, gastrointestinal tract, lung, thymus and pituitary, usually present at an advanced metastatic stage, and are increasing in incidence and prevalence as awareness and diagnostic techniques have improved. Treatments for NETs including surgery, drugs (e.g. somatostatin analogues), chemotherapy, radiotherapy and radionuclide therapy, are often not effective and as such additional therapeutic agents a...